Draft NICE decision rejects Respreeza for incurable, genetic disorder
NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in adults with severe alpha-1-proteinase inhibitor deficiency.
Read More
Tag: Respreeza
Six new drugs win funding nod for NHS Scotland
Treatment cost regulators for the NHS in Scotland have approved routine funding for six medicines, offering patients new treatment options for blood cancer, skin cancer, high cholesterol, diabetes, psoriatic arthritis, and infections in people with cystic fibrosis.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
